Overview Dividends

(EXPO) Exponent - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US30214U1025

Consulting, Analysis, Testing, Risk

Research & Consulting Services
Market Cap in USD: 3,543m

IPO / Inception: 1990-08-17
Return 12m vs S&P 500: -29.7%

EPS (Earnings per Share)

EPS CAGR: -48.68%
EPS Trend: -36.6%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: 3.89%
Rev. Trend: 66.2%

Last SUE: 1.02
Qual. Beats: 1

Dividends

Dividend Yield	1.61%
Yield on Cost 5y	1.36%
Yield CAGR 5y	10.67%
Payout Consistency	100.0%
Payout Ratio	59.4%

Risk via 5d forecast
Volatility	25.7%
Value at Risk 5%th	38.5%
Relative Tail Risk	-9.14%

Reward TTM
Sharpe Ratio	-0.73
Alpha	-25.04
CAGR/Max DD	-0.20

Character TTM
Hurst Exponent	0.291
Beta	0.523
Beta Downside	0.243

Drawdowns 3y
Max DD	42.55%
Mean DD	21.66%
Median DD	20.86%

Description: EXPO Exponent January 11, 2026

Exponent, Inc. (NASDAQ: EXPO) is a science- and engineering-consulting firm that serves a broad spectrum of industries through two operating segments: Engineering & Other Scientific, and Environmental & Health.

The Engineering segment delivers expertise in biomechanics, biomedical engineering, civil/structural engineering, data science, electrical/computer engineering, materials science, mechanical engineering, polymer chemistry, thermal sciences, and vehicle engineering. The Environmental & Health segment focuses on chemical regulation, food safety, ecological and biological sciences, environmental and earth sciences, and health sciences, plus proactive/reactive product safety, litigation support, and regulatory services.

Key customers span chemicals, construction, consumer products, energy, food & beverage, government, life sciences, insurance, manufacturing, technology, industrial equipment, and transportation, reflecting the firm’s diversified revenue base.

Recent performance highlights (FY 2023) include revenue of approximately $1.0 billion, an operating margin near 13 %, and a backlog exceeding $1.2 billion, indicating strong demand for consulting services amid heightened ESG compliance and rising product-liability litigation. The sector is further buoyed by increased regulatory scrutiny in chemicals and food safety, which drives steady growth for firms with deep technical expertise.

For a deeper quantitative assessment, you might explore ValueRay’s analyst notes on EXPO.

Piotroski VR‑10 (Strict, 0-10) 5.0

Net Income (104.8m TTM) > 0 and > 6% of Revenue (6% = 34.3m TTM)

FCFTA 0.16 (>2.0%) and ΔFCFTA -4.49pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 45.86% (prev 49.17%; Δ -3.31pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.17 (>3.0%) and CFO 132.2m > Net Income 104.8m (YES >=105%, WARN >=100%)

Net Debt (-124.8m) to EBITDA (149.5m) ratio: -0.83 <= 3.0 (WARN <= 3.5)

Current Ratio 2.69 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (51.5m) change vs 12m ago -0.33% (target <= -2.0% for YES)

Gross Margin 40.33% (prev 44.60%; Δ -4.27pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 75.90% (prev 75.12%; Δ 0.78pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM)

Altman Z'' 8.29

(A) 0.34 = (Total Current Assets 416.8m - Total Current Liabilities 154.8m) / Total Assets 761.4m

(B) 0.87 = Retained Earnings (Balance) 658.8m / Total Assets 761.4m

warn (B) unusual magnitude: 0.87 — check mapping/units

(D) 1.83 = Book Value of Equity 656.5m / Total Liabilities 358.6m

Total Rating: 8.29 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 79.85

1. Piotroski 5.0pt

2. FCF Yield 3.60%

3. FCF Margin 21.51%

4. Debt/Equity 0.21

5. Debt/Ebitda -0.83

6. ROIC - WACC (= 17.01)%

7. RoE 24.77%

8. Rev. Trend 66.19%

9. EPS Trend -36.60%

What is the price of EXPO shares?

As of January 11, 2026, the stock is trading at USD 74.59 with a total of 384,236 shares traded.
Over the past week, the price has changed by +6.33%, over one month by +5.17%, over three months by +14.73% and over the past year by -15.00%.

Is EXPO a buy, sell or hold?

Exponent has received a consensus analysts rating of 3.67. Therefor, it is recommend to hold EXPO.

Strong Buy: 1
Buy: 0
Hold: 2
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the EXPO price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	85.5	14.6%
Analysts Target Price	85.5	14.6%
ValueRay Target Price	77.4	3.8%

EXPO Fundamental Data Overview January 05, 2026

P/E Trailing = 34.5567
P/E Forward = 31.4465
P/S = 6.6699
P/B = 8.6868
P/EG = 3.14
Beta = 0.821
Revenue TTM = 571.4m USD
EBIT TTM = 144.5m USD
EBITDA TTM = 149.5m USD
Long Term Debt = 82.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 6.49m USD (from shortTermDebt, last quarter)
Debt = 82.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -124.8m USD (from netDebt column, last quarter)
Enterprise Value = 3.42b USD (3.54b + Debt 82.6m - CCE 207.4m)
Interest Coverage Ratio = unknown (Ebit TTM 144.5m / Interest Expense TTM 0.0)
EV/FCF = 27.81x (Enterprise Value 3.42b / FCF TTM 122.9m)
FCF Yield = 3.60% (FCF TTM 122.9m / Enterprise Value 3.42b)
FCF Margin = 21.51% (FCF TTM 122.9m / Revenue TTM 571.4m)
Net Margin = 18.35% (Net Income TTM 104.8m / Revenue TTM 571.4m)
Gross Margin = 40.33% ((Revenue TTM 571.4m - Cost of Revenue TTM 340.9m) / Revenue TTM)
Gross Margin QoQ = 24.94% (prev 16.43%)
Tobins Q-Ratio = 4.49 (Enterprise Value 3.42b / Total Assets 761.4m)
Interest Expense / Debt = 7.77% (Interest Expense 6.42m / Debt 82.6m)
Taxrate = 27.38% (10.6m / 38.6m)
NOPAT = 105.0m (EBIT 144.5m * (1 - 27.38%))
Current Ratio = 2.69 (Total Current Assets 416.8m / Total Current Liabilities 154.8m)
Debt / Equity = 0.21 (Debt 82.6m / totalStockholderEquity, last quarter 402.9m)
Debt / EBITDA = -0.83 (Net Debt -124.8m / EBITDA 149.5m)
Debt / FCF = -1.02 (Net Debt -124.8m / FCF TTM 122.9m)
Total Stockholder Equity = 423.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 13.93% (Net Income 104.8m / Total Assets 761.4m)
RoE = 24.77% (Net Income TTM 104.8m / Total Stockholder Equity 423.3m)
RoCE = 28.57% (EBIT 144.5m / Capital Employed (Equity 423.3m + L.T.Debt 82.6m))
RoIC = 24.79% (NOPAT 105.0m / Invested Capital 423.3m)
WACC = 7.79% (E(3.54b)/V(3.63b) * Re(7.84%) + D(82.6m)/V(3.63b) * Rd(7.77%) * (1-Tc(0.27)))
Discount Rate = 7.84% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 0.01%
[DCF Debug] Terminal Value 78.52% ; FCFF base≈135.1m ; Y1≈131.9m ; Y5≈132.9m
Fair Price DCF = 51.58 (EV 2.45b - Net Debt -124.8m = Equity 2.57b / Shares 49.9m; r=7.79% [WACC]; 5y FCF grow -3.46% → 2.90% )
EPS Correlation: -36.60 | EPS CAGR: -48.68% | SUE: -4.0 | # QB: 0
Revenue Correlation: 66.19 | Revenue CAGR: 3.89% | SUE: 1.02 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.55 | Chg30d=+0.002 | Revisions Net=+2 | Analysts=3
EPS next Year (2026-12-31): EPS=2.23 | Chg30d=-0.120 | Revisions Net=+3 | Growth EPS=+8.4% | Growth Revenue=+7.5%

Additional Sources for EXPO Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle